ATE208629T1 - Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung - Google Patents

Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung

Info

Publication number
ATE208629T1
ATE208629T1 AT97936364T AT97936364T ATE208629T1 AT E208629 T1 ATE208629 T1 AT E208629T1 AT 97936364 T AT97936364 T AT 97936364T AT 97936364 T AT97936364 T AT 97936364T AT E208629 T1 ATE208629 T1 AT E208629T1
Authority
AT
Austria
Prior art keywords
glycoconjugates
neisseria meningitidis
meningitidis serogroup
vaccine formulations
methods
Prior art date
Application number
AT97936364T
Other languages
English (en)
Inventor
Robert C Seid
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21820678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE208629(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE208629T1 publication Critical patent/ATE208629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AT97936364T 1996-08-27 1997-08-04 Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung ATE208629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2445496P 1996-08-27 1996-08-27
PCT/US1997/013609 WO1998008543A1 (en) 1996-08-27 1997-08-04 Neisseria meningitidis serogroup b glycoconjugates and methods of using the same

Publications (1)

Publication Number Publication Date
ATE208629T1 true ATE208629T1 (de) 2001-11-15

Family

ID=21820678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936364T ATE208629T1 (de) 1996-08-27 1997-08-04 Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung

Country Status (10)

Country Link
US (2) US6638513B2 (de)
EP (1) EP0939647B2 (de)
JP (2) JP4162267B2 (de)
AT (1) ATE208629T1 (de)
CA (1) CA2264735C (de)
DE (1) DE69708318T3 (de)
DK (1) DK0939647T4 (de)
ES (1) ES2166097T5 (de)
PT (1) PT939647E (de)
WO (1) WO1998008543A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922059B1 (de) 1996-08-27 2003-10-22 Chiron Corporation Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
JP4162267B2 (ja) * 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
EP0994723A1 (de) 1997-06-24 2000-04-26 Chiron Corporation Verfahren um erwachsenen mit anti-meningokokken impfstoffzusammensetzungen zu immunizieren
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
ES2278446T3 (es) * 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
RU2322451C2 (ru) 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003080678A1 (en) * 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
WO2006002402A2 (en) * 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
JP5702600B2 (ja) * 2007-07-03 2015-04-15 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド オリゴシアル酸誘導体、製造方法および免疫学的使用
AU2011288203A1 (en) * 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
WO2014014821A1 (en) 2012-07-19 2014-01-23 Redwood Biosciences, Inc. Antibody specific for cd22 and methods of use thereof
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP3798228A1 (de) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen und -erkrankungen
KR101980989B1 (ko) * 2012-12-20 2019-05-21 화이자 인코포레이티드 당접합 방법
SG11201504815QA (en) 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EA039554B1 (ru) 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
EP4098276A1 (de) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
WO2015081085A2 (en) 2013-11-27 2015-06-04 Ipierian, Inc. Methods of treating a tauopathy
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US10934347B2 (en) 2016-04-04 2021-03-02 Genzyme Corporation Anti-complement factor BB antibodies and uses thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) † 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4727136A (en) † 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
WO1991008772A1 (en) 1989-12-14 1991-06-27 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
WO1996040225A1 (en) * 1995-06-07 1996-12-19 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
JP4162267B2 (ja) * 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
EP0922059B1 (de) 1996-08-27 2003-10-22 Chiron Corporation Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
EP0994723A1 (de) * 1997-06-24 2000-04-26 Chiron Corporation Verfahren um erwachsenen mit anti-meningokokken impfstoffzusammensetzungen zu immunizieren
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b

Also Published As

Publication number Publication date
WO1998008543A1 (en) 1998-03-05
US20020034518A1 (en) 2002-03-21
EP0939647A1 (de) 1999-09-08
US6638513B2 (en) 2003-10-28
ES2166097T3 (es) 2002-04-01
US7169392B2 (en) 2007-01-30
DE69708318T3 (de) 2006-11-16
CA2264735C (en) 2008-01-29
DK0939647T4 (da) 2006-10-23
DE69708318T2 (de) 2002-07-11
JP4162267B2 (ja) 2008-10-08
DE69708318D1 (de) 2002-01-03
EP0939647B2 (de) 2006-07-12
DK0939647T3 (da) 2002-04-02
CA2264735A1 (en) 1998-03-05
EP0939647B1 (de) 2001-11-14
JP2008201793A (ja) 2008-09-04
US20040052805A1 (en) 2004-03-18
HK1021145A1 (en) 2000-06-02
ES2166097T5 (es) 2007-03-16
PT939647E (pt) 2002-04-29
JP2001500540A (ja) 2001-01-16

Similar Documents

Publication Publication Date Title
ATE208629T1 (de) Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
FR2662701B1 (fr) Composition tinctoriale a base de 5,6-dihydroxyindolines et procede de teinture des fibres keratiniques.
NO973059L (no) Hydroksylaminderivater som er anvendbare for å öke den molekylære chaperonproduksjon, og fremstilling derav
DK1235589T3 (da) Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen
ATE208772T1 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
NO308029B1 (no) Inhibitorer av <beta>-amyloidproteinproduksjon og farmasøytisk preparat inneholdende disse
PT1007043E (pt) Metodo para o tratamento de doencas de armazeamento lisossomico com envolvimentode cns
DK1049700T3 (da) Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf
ATE207365T1 (de) Polyribosylribitol-phosphat enthaltende haemophilus-influenzae-typ-b-impfstoffzubereitu g und verfahren zu deren herstellung
DK0614362T3 (da) Farmaceutiske præparater på basis af ebastin og dermed analoge forbindelser
DK217588A (da) 17beta-(cyclopropylamino)-androst-5-en-3beta-olderivater, deres fremstilling og anvendelse som laegemidler
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
DE58902712D1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
HU912486D0 (en) Process for producing ethers and thioethers of piperidyl
SG48816A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
ATE277907T1 (de) Blutzuckersenkende und lipidsenkende verbindungen
Mizuochi et al. The structures of the carbohydrate moieties of bovine blood coagulation factor IX (Christmas factor).
AR041116A1 (es) Metodos para tratar pacientes que sufen el sindrome de piernas inquietas o desordenes relacionados
SE9400524L (sv) Energipreparat
DE69619868D1 (de) Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
NO964652L (no) Fremgangsmåte for fremstilling av 1-(3-trialkylsilyl-fenyl)-2,2,2-trifluormetyletanonderivater
DK0744951T3 (da) Fremgangsmåde til fremstilling af en steril prednisolongen
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0939647

Country of ref document: EP

EEFA Change of the company name